Cover Image
市場調查報告書

白細胞介素7受體亞單位α:開發中產品分析

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 365742
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素7受體亞單位α:開發中產品分析 Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H1 2018
出版日期: 2018年01月18日 內容資訊: 英文 35 Pages
簡介

本報告提供以白細胞介素7受體亞單位α為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白細胞介素7受體亞單位α 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Cytheris SA
  • Genexine, Inc.
  • GlaxoSmithKline Plc
  • OSE Immunotherapeutics
  • Pfizer Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1253TDB

Summary:

According to the recently published report 'Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H1 2018'; Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis.

The report 'Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H1 2018' outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Metabolic Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders, Infectious Disease and Women's Health which include indications Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Cervical Intraepithelial Neoplasia (CIN), Crohn's Disease (Regional Enteritis), Human Papillomavirus Infections, Lymphocytopenia, Multiple Sclerosis, Non-Small Cell Lung Cancer, Solid Tumor, Transplant Rejection and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
  • The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Overview
    • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Companies Involved in Therapeutics Development
    • Genexine Inc
    • OSE Immunotherapeutics
    • Pfizer Inc
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles
    • Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GXI-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSE-127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSE-703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06342674 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Dormant Products
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Discontinued Products
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 19, 2017: OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases
      • Dec 14, 2017: OSE Immunotherapeutics Receives a Grant from French Government Program "Fonds Unique Interministeriel" to Explore New Cytotoxic Antibodies
      • Jun 21, 2017: OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
      • Jun 15, 2017: OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies Conference
      • Jul 22, 2016: Genexine Confirms Possibility of Treatment in Cervicovaginal Tumor with Combination Therapy of hyFc-fused Interleukin-7 and HPV DNA Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Genexine Inc, H1 2018
  • Pipeline by OSE Immunotherapeutics, H1 2018
  • Pipeline by Pfizer Inc, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top